Skip to main content
S&P 5007,592.40-0.35%DOW52,297.09-0.36%NASDAQ25,366.09-0.39%BTC$69,261.00-4.96%ETH$1,961.25-2.98%GOLD$3,894.10+0.23%OIL$88.71-0.03%
Smart Investors Daily
SID Premium
RN

NASDAQ · RNA

Avidity Biosciences, Inc.

Healthcare · Biotechnology

$7.50

Down-$0.46 (-5.78%)

Updated Nov 13, 2026, 12:50 PM

SID Score

4.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
9.4B
P/E ratio
-20.36
Dividend yield
0.00%
52-week range
$7.49 – $73.06
Volume
294.72K
Avg. volume
5.22M

Price performance · RNA

RNA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

RNA closed at $7.50 after 21 trading sessions, down 4.09% for the selected period.

Last close
$7.50
Period change
-4.09%
Period low
$7.50
Period high
$8.72
Daily close
View OHLC price history
RNA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$7.89$7.89$7.49$7.50294.72K
Nov 11, 2026$8.23$8.2599$7.93$7.96131.83K
Nov 10, 2026$8.30$8.40$8.11$8.23108.83K
Nov 9, 2026$8.42$8.4625$8.20$8.38138.12K
Nov 6, 2026$8.32$8.55$8.23$8.34108.19K
Nov 5, 2026$8.68$8.73$8.29$8.32193.9K
Nov 4, 2026$8.85$8.99$8.50$8.68136.79K
Nov 3, 2026$8.57$8.77$8.45$8.72280.93K
Nov 2, 2026$8.22$8.64$8.185$8.55470.07K
Oct 30, 2026$8.19$8.31$7.88$8.27566.64K
Oct 29, 2026$8.52$8.65$8.20$8.26155.78K
Oct 28, 2026$8.14$8.45$8.14$8.40233.6K
Oct 27, 2026$8.05$8.3895$8.05$8.32198.57K
Oct 26, 2026$8.20$8.23$7.98$8.05187.42K
Oct 23, 2026$8.06$8.21$7.78$8.20192.66K
Oct 22, 2026$8.01$8.185$7.945$8.16173.48K
Oct 21, 2026$7.97$8.32$7.96$8.00193.21K
Oct 20, 2026$7.75$8.27$7.71$7.98289.49K
Oct 19, 2026$7.68$7.87$7.49$7.61243.91K
Oct 16, 2026$7.79$8.06$7.67$7.67190.98K
Oct 15, 2026$7.75$7.87$7.64$7.82131.24K

Latest RNA news

The latest Smart Investors Daily articles mentioning RNA.

Stock researchCompany · Overview

RNA research

Overview

Company profile and research snapshot.

Company profile

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$74.44
Implied upside
—
Analysts
—
RNA recent ratings
DateFirmRatingTarget
Oct 28, 2026HC Wainwright & Co.Buy—
Oct 22, 2026Roth CapitalBuy—
Aug 14, 2026HC Wainwright & Co.Buy—
Aug 6, 2026HC Wainwright & Co.Buy—
Jun 18, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 2, 2026

Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026

Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome during Hypertrophic Cardiomyopathy Medical Society at the American Heart Association Scientific Sessions 2026,

Benzinga · Nov 2, 2026

Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy

Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndromeThe nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2 syndrome developed by

Yahoo · Oct 27, 2026

Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome. The Company expects to report initial proof-of-concept data from Corven

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By